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Because of increasing bacterial resistance worldwide, 
the search for new antibacterial agents is more pressing 
than ever. Advances achieved with the extended broad- 
spectrum 0-lactams and the quinolones against a large 
number of pathogens have been compromised over the 
last few years by bacteria carrying novel p-lactamases 
and/or chromosomal mutations of penicillin-binding 
proteins and/or the DNA gyrase A and/or other 
forms of resistance affecting these agents. However, 
researchers from Korea (LG Chemical Ltd, Tae Jon) 
have described a novel fluoronaphthyridone with a 
vicinal substitution (3-aminomethyl;4-methyloxyin1ino) 
at the 7-pyrrolidine ring that enhances potency against 
some resistant pathogen? [1,2]. The novel agent has 
demonstrated improved activity primarily against Gram- 
positive cocci in expanded studies 131. In light of 
the evolving international antiniicrobial resistance 
problems, we evaluated this promising compound in 
four large medical centers (two in the USA. and two 
in Switzerland) against a broad range of routinely 
isolatcd, non-fastidious pdthogens. 
Bacterial strains 
A total of 379 aerobic bacterial strains (mostly recent 
single-patient clinical isolates from universit)- medical 
centers) \vere tested in Basel ( K = 7 5 ) ,  Cleveland 
(S= 100). Iowa City (S= 104), and Ziirich (.\= 104). 
Representative members of species that pose anti- 
microbial resistance problems were selected from among 
the most commonly encountered bacteria in each 
laboratory. Of  these, 260 isolates were Gram-negative, 
and 119 were Gram-positive. They were identified by 
standard methods 141. 
Susceptibility tests 
Prefabricated 90-well inicrotitcr plates with seri'xl tWo- 
fold decreasing antimicrobial concentrations in cation- 
adjusted Miieller-Hinton broth (Becton-Dickinson, 
Cockeysville. MD, USA) were obtained from a 
commercial manufacturer (PML Microbiologicals, 
Tualatin, OR. USA) and distributed at -7OOC to the 
participating laboratories. The minimum inhibitory 
concentrations (MIC) Lvere determined as recon- 
mended by the National Committee for Clinical 
Laboratory Standards (NCCLS) [ S ] .  The compounds 
were provided bv their respective manufacturers: 
LB20304 from LG Chemical Ltd, ciprofloxacin from 
Miles Pharmaceuticals (West Haven, CT, USA), 
clinafloxacin (formerly CI-960) from Parke-Davis. Inc. 
(Ann Arbor, MI, USA), fleroxacin &om E Hofhann-  
LaRoche AG (Basel, Switzerland), ofloxacin from 
Ortho-McNeil Pharmaceuticals (Karitan, NJ, USA), 
sparfioxacin from Khone-Poulenc Korer (Collegeville, 
PA, USA), and trovafloxacin (formerly CP99,219) from 
Pfizer, Inc. (Central Research, Groton, CT. USA). The 
tested range of serial two-fold dilutions (1 1 dilutions) 
extended from 5 0.008 mg/L to 8 mg/L and was equal 
for all d ruF  tested. The MIC was defined as the lowest 
concentration which yielded n o  visible growth. Faint 
hazes were disregarded. The MIC breakpoints applied 
for susceptible and resistant categories were taken from 
the current NCCLS guidelines [i]. For compounds 
without published criteria. we determined the percen- 
tage of susceptible strains at  two potential, commonly 
used breakpoint concentrations ( 1  mg/L; 2 rng/L) 
for fluoroquinolones 15). Standard quality control, 
American Tvpe Culture Collection (ATCC) strains 
included Escliericlzin roli ATCC 15922. Erircrocoicrrs 
l;leculi.i ATCC 2921 2. Stapl~ylocorcirs m r e u s  ATCC 
29213. and Psci.rdoriiorins ilerbtqirrosa ATCC 27853. 
Because all testing was performed with the same lot of 
prefabricated trays, all quality control values were found 
within the recommended ranges, and the susceptibility 
ranges and potencies of the tested bacteria from the 
different centers for each group of isolates were not 
significantly different. we pooled the antiniicrobial 
susceptibility test data of the four participant labora- 
tories. 
The percentage of non-fastidiouc aerobically grow- 
ing Gram-positive cocci susceptible to LB20304 was 
most similar to that of trovafloxacin and clinafloxxin, 
but higher than that of sparfloxacin, ofloxacin, cipro- 
floxacin and fleroxacin (Table 1). The activity of all 
compounds W~IS subctantial1)- lower ag;ilnst oxacillin- 
resistant than against oxacillin-susceptible stapliylo- 
cocci, particularly Stqdzylororrirs ilurivrs (e.g.  93% versus 
13% for ciprofloxacin). (:oagulase-negative staphylo- 
cocci exhibited this difference only when the MICOO 
results for the oxacillin-resistant strains were compared. 
Whereas LB2U304, clinaflosacin and trovafloxacin 
showed activity against a majority of oxacillin-resistant 
S r ~ ~ p l i y l o c o ~ ~ u s  illireus strains, the older riiarketed fluoro- 
quinolones (ciprofloxacin, ofloxacin, spadoxacin. and 
fleroxacin) were at least modectly active against some of 
these strains. At 2 mg/L clinafloxacin, trovafloxacin, 
and LB203O.C inhibited at  least 60% of E~tcrorocctrs 
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Table 1 In vitro activity of LB20304 compared to six other quinolones tested against 119 strains of Gram-positive cocci and 
260 strains of Gram-negative bacilli 
~ ~~ 
MIC (rng/L) 94 at MIC (mg/L)” 
Organism (no. tested) Quinolone 50% 90% Range <1 <2 
Staphylototcus aureus 
Oxacillin susceptible (29) LB20304 
Ciprofloxacin 
Clinafloxacin 
Flerosacin 
Ofloxacin 
SparAoxacin 
Trovafloxacin 
OxaciUin remtant (I 5) LB20304 
Ciprofloxacin 
Clinafloxacin 
Fleroxacin 
Ofloxacin 
Sparfloxacin 
Trovafloxacin 
CoabJulase negative 
,taphylococci 
Oxacillin suscepnblr (14) L820.304 
Ciprofloxacin 
Clinafloxacin 
Fleroxacin 
Ofloxacin 
Sparfloxacm 
Trovafloxacin 
Oxacdlin resistant (26) 
.lcirretoboitrr spp. (1 1) 
LB20304 
Ciprofloxacin 
Clinafloxacin 
Fleroxacin 
Ofloxacin 
SparAoxacin 
Trovafloxacin 
LB203OJ 
Ciprofloxacin 
Clinafloxacin 
Fleroxacin 
Ofloxacin 
Sparfloxacin 
Trovafloxacin 
LB20304 
Ciprofloxacin 
Clinafloxacin 
Flrroxacin 
Ofloxacin 
Sparilosacin 
Trovafloxacin 
LB20304 
Ciprofloxacin 
Clinafloxacin 
Fleroxacin 
Ofloxacin 
Spartloxacin 
Trovafloxacin 
0.015 0.0.3 
0.25 1 
0.015 0.03 
0.5 1 
0.25 1 
0.12 0.25 
0.015 0.0tI 
0.015 0.00 
0.25 2 
0.03 0.0h 
1 > 8  
0.5 4 
0.12 0.5  
0.03 0.00 
0.015 4 
0.25 >8 
0.0 1 5 t 
1 >8 
0.5 >8 
0.12 >8 
0.03 >8 
0.06 - 3
1 >8 
0.12 2 
4 >8 
2 >8 
1 > 8  
0.25 8 
1 >8 
- > 8  
0.5 8 
8 >8 
4 > a  
2 >8 
1 4 
3 
5 0.0O8-0.5 
0.12-2 
5 0.008-0.5 
0.25-4 
0.25-2 
U.il15-0.5 
<0.008-0.5 
0.015 to >8 
0.25 to > 8  
0.015-4 
0.5 to >8 
0.25 to >8 
0.06 to >8 
0.0 1 5-8 
<0.(J08-0. 12 
0.12-4 
0.015-0.06 
0.5 to >8 
0.25-4 
0 . 0 6 2  
0.0 15-0.5 
20.008 to >8 
0.06 to >8 
0 008 to >8 
0 25 to > 8  
0 12 to >8 
0 06 to >8 
20 008 to >8 
0.015 to >8 
0.25 to > 8  
9.03 to > 8  
1 t o > 8  
1 to >8 
0.12 to >8 
0.03 to >8 
0.06 to >8 
1 to >8 
0.12 to >8 
4 to >8 
2 to > a  
0.5 to >8 
0.25 to >8 
0.015 to >8 
0 03 to > 8  
0.008 to > 8  
0.12 to >8 
0.12 to >8 
50.008 to >8 
<O 008 to >8 
100 
100 
93 
93 
(100) 
100 
47 
(13) 
60 
7 
20 
67 
(93) 
(20) 
100 
100 
79 
86 
100 
81 
(69) 
92 
62 
69 
77 
88 
88 
4 
12 
(79) 
(93) 
(69 
(56) 
(88) 
88 
6 0 
60 
0 
0 
(30) 
(20) 
50 
45 
55 
45 
36 
45 
(36) 
(45) 
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Table 1 continued 
MIC (mg/L) 96 at M l C  (nig/L) 
Organism (no. rested) Quinoloiie i O % l  
Psrirdonrorm aenqinosa (30) LB20304 
C:iprofloxacin 
Clinafloxaciri 
Flcroxaciri 
Ofloxacin 
Sparfloxacin 
Trovafloxacin 
Sreriurroykotiiotius malrophilia (1 1) LB20304 
Ciprofloxacin 
Clinafloxacin 
Fleroxacin 
Ofloxacin 
Spartloxacin 
Trovafloxacin 
LU20304 
Ciprofloxacin 
Clinafloxacin 
Fleroxacin 
Ofloxacin 
Spartloxacin 
Trovafloxacin 
Eiirerobairrr n m , p e x  (1  5) L820304 
Ciprofloxacin 
Clinafloxacin 
Fleroxacin 
Ofloxacin 
Spartloxacin 
Trovafloxacin 
Eiirerohacter ihacac  (20) 
Escherirhia roli (58) 
LB2030-1 
Ciprofloxacin 
Clinafloxacin 
Fleroxacin 
Ofloxacin 
Spadoxacin 
Trovafloxacin 
LB20304 
Ciprofloxacin 
Clinafloxacin 
Fleroxacin 
Ofloxacin 
Sparfloxaciri 
Trovafloxacin 
Klebsiella yrieirtnoriiae (28)  LU20304 
Ciprofloxacin 
Clinafloxacin 
Fleroxacin 
Ofloxa ciii 
Sparfloxaon 
Trovafloxacin 
0.25 
0.1, 
0.12 
I 
2 
1 
0 . i  
0 3  
1 
11.12 
1 
1 
0.25 
0.25 
0.03 
0.015 
O.(Il 5 
0.12 
0.25 
0.12 
0.03 
0.03 
0.0lj 
(1.013 
i). 12 
0.12 
0.12 
0.06 
0.i 1 I 5 
0.015 
10.008 
0.06 
0.12 
0.06 
0.03 
0.015 
20.008 
~ 0 . 0 0 X  
0.06 
0.06 
0.03 
0.01 .i 
0.03 
11.03 
0.01 5 
0.12 
0.12 
0.12 
0.06 
8 
4 
0.5 
8 
>8 
4 
4 
0.s 
(I. I2 
(I. 12 
0.5 
0.5 
1 
0.5 
0 . 3  
0.25 
(I.  12 
1 
1 
1 
0.3 
0. 12 
il. 12 
0.06 
(1.75 
0.5 
0.2.3 
(1.12 
0.06 
0.06 
0.01 5 
0.73 
0.25 
(I. 12 
0.06 
1 
1 
O..i 
4 
1 
7 - 
3 - 
Kangc 51 12 
11.015 t o  >8 
<0.008 to >8 
50.008 to >8 
0.06 to >8 
0.06 ro >S 
0.25 to >8 
0.12 ro >8 
0.25 to >8 
0.25 to >8 
0.03- 1 
0.3 to >8 
0.5 to >X 
0.12 to >8 
0.06 to >8 
10.1108 to I8 
10.1108 to >x 
10.(108 to 2 
0.03 ro >X 
(1.03 to >8 
0.03 to >8 
0.015 to >8 
0.015-0.25 
<0.008-X 
1(1.008-(1.2.5 
0.06-8 
(I.(l6-8 
0.03-2 
0.0 1 5-0.5 
<O.M8-0.25 
10.008-0.25 
<0.00X-O.(i6 
0.03-0.5 
0.03-1 
0.01 5-0.5 
10.008-0.25 
77 
87 
53 
47 
73 
(H(J) 
(60) 
64 
(55) 
l(l0 
.. 
35 
33 
_. 
(73) 
7.3 
9 4 
91 
94 
91 
94 
(9-1) 
(94) 
100 
(03) 
100 
93 
93 
100 
(93) 
I 110 
( 1  00) 
100 
100 
I I J I I  
(100) 
100 
97 
(97) 
9 7 
97 
9.5 
(97) 
97 
96 
(93) 
9 G 
82 
82 
(86) 
96 
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Table 1 continued 
MIC (nig/L) % at MIC (mg/L).’ 
Organism (no. tested) Quinolone 50% 90% Range 1 1  2 2  
f loteus mirabilis (19) 
Serratia marresretrs (20) 
Other (31)b 
Enterobacteriaceae 
LB20304 0.12 0.5 0.06 to >8 95 95 
Ciprofloxacin 0.03 0.06 10.008 to >8 (95) 95 
Clinafloxacin 0.015 0.06 20.008 to >8 95 100 
Fleroxacin 0.12 0.25 0.03 to >8 95 (95) 
Ofloxacin 0.12 0.5 0.06 to >8 95 (95) 
Sparfloxacin 0.5 2 0.25 to >8 (89) 95 
Trovafloxacin 0.25 0.5 0.12 to >8 95 95 
LB20304 0.25 8 
Clinafloxacin 0.06 1 
Fleroxacin 0.25 8 
Ofloxacin 0.5 8 
Trovafloxacin 0.5 8 
Ciprofloxacin 0.12 4 
Sparfloxacin 1 8 
0.12 to >8 75 80 
0.015-4 90 90 
0.03 to 28 (80) 80 
0.06 to >8 70 (75) 
0.12 to >8 70 (80) 
0.25 to >8 (50) 75 
0.12 to >8 65 75 
LB20304 0.06 2 10.008 to >8 87 90 
Ciprofloxacin 0.01 5 0.12 10.008 to >8 (90) 94 
Clinafloxacin 20.008 0.06 10.008 to >8 100 100 
90 (90) Fleroxacin 0.06 0.25 10.008 to >8 
Ofloxacin 0.12 0.5 0.03 to >8 90 (90) 
Sparfloxacin 0.12 4 0.015 to >8 (87) 87 
Trovafloxacin 0.06 1 0.008-8 94 97 
Percentages in parentheses indicates the NCCLS [5]  breakpoint for the susceptible interpretation. 
Includes Citrobarter koseri (two strains), Klebsiella oxytoca (nine strains), 1210rpriella morgar1ii (five strains), Proreus vu(yaris (five strains), 
Iloviderrria spp. (five strains), and Serratia liqrrefaciens (five strains) 
faeciurn strains, while fleroxacin was least active. Against 
the more common Enterococcus faecalis strains, only 
LB20304, clinafloxacin, sparfloxacin and trovafloxacin 
inhibited nearly 90% of strains at 1 mg/L. 
The activity of LB20304 against the Entero- 
bacteriaceae was generally two-fold less than that of 
ciprofloxacin or clinafloxacin, but equal to or two-fold 
more than that of trovafloxacin (Table 1). Clinafloxacin 
was slightly more active (MIC50, 1 mg/L) against 
Acinetobacter spp., but only 36% (ciprofloxacin) to 45% 
(three drugs) of recent clinical isolates were inhibited 
by currently available compounds. Pseudornonas amginosa 
was most susceptible to clinafloxacin (87% inhibited 
at I 1  mg/L), yet LB20304 inhibited 80% of these 
strains at  5 2 mg/L, e.g. equal to ciprofloxacin. Among 
the currently available drugs tested, fleroxacin had 
the greatest activity (73%) versus Stenotrophomonas 
rnaltophilia, followed by ofloxacin and ciprofloxacin 
(55%). LB20304 inhibited (MICjo, 0.5 mg/L) 82% 
of these strains at 5 2  mg/L and clinafloxacin had the 
greatest potency (MIC~O,  0.5 mg/L). Overall, against 
the Gram-negative strains, the seven compounds only 
varied in spectrum from 83% to 94% at I 1  mg/L 
(investigational drugs) or at NCCLS published break- 
points for susceptibility [5]. 
The overall percentage of susceptible strains for 
LB20304, clinafloxacin and trovafloxacin were con- 
sistently higher at 1 mg/L or at  2 mg/L compared to 
those of the older fluoroquinolones. For the investiga- 
tional quinolones, the rank order of spectra (“XI inhibited 
at 51  mg/L) was clinafloxacin (92%) > LB20304 and 
trovaflo~xacin (87%). 
The observation that the overall percentage of 
susceptible strains to ciprofloxacin, ofloxacin, fleroxacin 
and sparfloxacin did not exceed 80% among species 
prone to quinolone resistance illustrates that these 
compounds have lost potency and spectrum in recent 
years within the study centers and nations monitored. 
However, the investigational compounds LB20304, 
clinafloxacin and trovafloxacin demonstrated that im- 
proved activity against Gram-positive organisms can be 
achieved among the quinolone class members without 
undue sacrifice of potency against important Gram- 
negative organisms. Clinafloxacin was the most potent 
of the agents tested [6]. Pharmacokinetic publications 
favor an interpretive breakpoint of 1 mg/L or lower for 
this drug, a breakpoint recently accepted by the 
NCCLS for sparfloxacin [5,7]. Trovafloxacin’s break- 
point for susceptibility is more likely to be at  1 or 
2 mg/L, depending on the final recommended dosage 
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and clinical tolerability 181. To date, limited human 
pharmacokmetic information has been published for 
LB20304, and therefore its activity relative to its 
comparators must remain an open question. The 
difference in possible MIC breakpoints (5  1 or < 2  
mg/L) between the latter two compounds has only 
minor repercussions on the percentage of susceptible 
isolates. indeed, the higher (I 2 mg/L) trovafloxacin 
and LB20304 breakpoints improved their spectra by 
only 3.2% and 2.4%, respectively. 
Other promising aspects of LB20304, clina- 
floxacin and trovafloxacin are their excellent activities 
against some fastidious species such as pneumococci, 
Haemophilus spp., and Movaxella catavrlialis [ 1-31; (not 
evaluated here). Therefore, these compounds should be 
very useful for the treatment of common bacterial 
respirator)- infections. Lastly, it may be speculated that 
LB20304-which is devoid of a halogen at the C-8 
position-would probably have lower rates of photo- 
toxicity in clinical trials than have been observed for 
sparfloxacin and clinafloxacin [6]. Accordingly, we 
await further clinical development of LB203CM and the 
other novel congeners utilized as comparison agents in 
this investigation. 
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Significant bacteriuria in infants and young children and 
relation to bacterial species and pyuria 
Chi ,\/licrobiol b z f c t  1998; 3: 284-287 
Urinary tract infection (UTI) is a common clinical 
problem in infants and young children, with a reported 
prevalence of 0.3-0.41'%, in randondy selected, asymp- 
tomatic infants [1,2], increasing to 5.3% in febrile 
infants 131. In this study we have assessed urine cultures 
by suprapubic bladder aspiration (SBA) in a population 
of infants and young children less than 36 months of 
age. Our aim was to define the level of bacteriuria to 
be expected in infection in this age group by using 
SBA. A second aim was to estimate the value of pyuria 
in the diagnosis of UTI. 
From January 1990 to December 1994. 5448 
infants and children younger than 36 months of 
age were admitted to the Department of Pediatrics, 
University of Patras Medical School, and 3225 (59.2%) 
of them had s i p s  of infection. UTI was considered as 
a probable diagnosis in 1300 of them, because one or 
